CRO Beaufort Introduce Quality Oversight Services
Clinical research organization (CRO) Beaufort has added quality oversight to its services for clients in the pharmaceutical , diagnostic, and medical device industries.
Beaufort has been engaged by a Top 20 Global Pharmaceutical Company to conduct quality oversight monitoring (QOM) visits for the company’s clinical trials.The partnership will help the company manage vendor quality and compliance during clinical trials in a uniform, quality-focused, efficient, and effective manner.
“The need for quality oversight monitoring continues to grow,” said John Wilson, Beaufort Senior Vice President of clinical operations. “Increased scrutiny and enforcement activity from the FDA and other regulatory agencies has heightened awareness among sponsors and CROs of the need to ensure the integrity of clinical research data.”
The Beaufort quality oversight team will provide the pharmaceutical company an understanding of how each of its studies is being conducted by the company’s other CROs. Beaufort will not audit the CROs, but will observe, critically assess and provide objective and unbiased feedback on the respective CRO clinical research associates’ level of knowledge, experience, and training for the specified trials. The company can then use those observations to provide feedback to the CRO.
Sponsors of clinical investigations, as well as CROs, have come under increased scrutiny recently from the Food and Drug Administration (FDA) for failing to ensure proper monitoring of clinical trials. The FDA holds sponsors ultimately responsible and accountable for the quality of work performed on their behalf. Recent FDA BIMO audits have cited numerous diagnostic, drug, and device companies for multiple issues such as:
-Failure to follow the protocol
-Failure to keep adequate and accurate records
-Problems with the informed consent form
-Failure to report adverse events
-Failure to account for the disposition of study drugs
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
